The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Hepatitis B Virus (HBV) Capsid Inhibitors Market Expected To Reach Based On Its 2026 Value?
The hepatitis b virus (hbv) capsid inhibitors market has experienced substantial growth in recent years. This market is projected to expand from $0.52 billion in 2025 to $0.59 billion in 2026, at a compound annual growth rate (CAGR) of 13.7%. The historical growth can be ascribed to the global burden of chronic hepatitis b infection, limitations of existing antiviral therapies, early clinical validation of capsid inhibitors, increased virology research funding, and growing pharmaceutical pipeline activity.
The hepatitis b virus (hbv) capsid inhibitors market is anticipated to experience swift expansion in the coming years. Its value is projected to reach $0.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.4%. This projected growth during the forecast period is fueled by factors such as the broader adoption of combination regimens involving immunotherapies, increased financial commitments to curative HBV therapies, a rise in regulatory clearances for new antivirals, expanding worldwide screening initiatives, and progress in next-generation capsid inhibitors. Key developments anticipated during this period encompass a heightened emphasis on functional cure strategies for HBV, the escalating development of capsid assembly modulators, evolving combination therapy methods, an expansion of late-stage clinical trial pipelines, and improved targeting of pathways involved in viral replication.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30294&type=smp
Which Important Drivers Are Guiding The Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth?
The growing incidence of hepatitis B virus infections is anticipated to boost the hepatitis B virus (HBV) capsid inhibitors market. Hepatitis B Virus (HBV) infections are liver ailments caused by the hepatitis B virus, leading to both acute and chronic conditions. These infections spread through contact with infected blood or bodily fluids and can result in severe complications such as liver cirrhosis or liver cancer. The increasing prevalence of Hepatitis B Virus (HBV) infections is primarily due to insufficient vaccination coverage, leaving a significant portion of the population unprotected and facilitating easier viral transmission via infected blood or bodily fluids. Hepatitis B virus (HBV) capsid inhibitors address hepatitis B virus (HBV) infections by disrupting the formation and assembly of the viral capsid, thereby inhibiting viral replication and reducing the spread of infection within the body. For instance, in April 2024, a report from the World Health Organization (WHO), a Switzerland-based intergovernmental organization, highlighted that by the end of 2022, only 13% of individuals with chronic hepatitis B had been diagnosed, and approximately 3% (7 million) had received antiviral treatment. For hepatitis C, 36% of affected individuals were diagnosed, with 20% (12.5 million) receiving curative therapy. These figures remain well below the global target of treating 80% of people living with chronic hepatitis B and C by 2030. Therefore, the increasing prevalence of hepatitis B virus infections is driving the expansion of the hepatitis B virus (HBV) capsid inhibitors market.
How Is Segmentation Applied In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Segment Analysis?
The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –
1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors
Which Trends Are Contributing To Changes In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?
Key companies active in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing the development of innovations, such as oral small molecule capsid assembly modulators, to enhance antiviral efficacy, boost patient compliance, and achieve lasting viral suppression. Oral small-molecule capsid assembly modulators are orally administered antiviral agents that disrupt the assembly of the hepatitis B virus (HBV) capsid, thereby blocking its replication and decreasing viral activity in the body. For example, in July 2024, Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical company, partnered with Xiamen Amoytop Biotech Co., Ltd., a China-based biopharmaceutical company, to commence a clinical trial evaluating novel treatment candidates for chronic hepatitis B (CHB). This initiative aims to leverage its advanced capsid assembly modulator technology to improve antiviral effectiveness and accelerate the development of next-generation HBV therapies. This launch signifies a vital step in advancing Aligos’s commitment to developing effective and potentially curative treatments for patients experiencing chronic hepatitis B.
Who Are The Companies Participating In The Hepatitis B Virus (HBV) Capsid Inhibitors Market Environment?
Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.
Get The Full Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:
Which Region Has The Greatest Market Share In The Hepatitis B Virus (HBV) Capsid Inhibitors Market?
Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hepatitis B Virus (HBV) Capsid Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hepatitis B Virus (HBV) Capsid Inhibitors Market 2026, By The Business Research Company
Hepatitis B Virus Hbv Market Report 2026
https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report
Preventive Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report
Chronic Hepatitis B Market Report 2026
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model